Posted by Michael Wonder on 11 Jan 2024
Arcutis Canada announces Health Canada acceptance of the supplement to a new drug submission for roflumilast 0.3% foam for the treatment of seborrheic dermatitis in individuals 9 years of age and older
8 January 2024 - Supplement to a new drug submission supported by positive Phase 2 and Phase 3 pivotal trial efficacy and safety results.
Arcutis Canada is pleased to announce that Health Canada has accepted for review the supplement to a new drug submission for roflumilast foam 0.3%, a steroid free, once daily phosphodiesterase 4 inhibitor for the topical treatment of seborrheic dermatitis in adult and adolescent patients 9 years of age and older.
